Belgium-based biotechnology company ThromboGenics has reported results from the Phase IIIb OASIS study of JETREA (ocriplasmin) in patients with symptomatic vitreomacular adhesion (sVMA).
JETREA is the company's lead product and is a proteolytic enzyme developed to treat sVMA.
The randomised, sham-controlled, double-masked Phase IIIb OASIS trial has been conducted over a period of two years.
It was designed to determine the long-term safety and efficacy offered by JETREA to patients suffering from sVMA who were administered with JETREA through an injection.
sVMA describes a condition whereby the separation of the central gel vitreous in the eye is not completely detached from the retina.
Small portions of vitreous cling to the macula, which is the part of retina responsible to generate vision.
The data was published in the AAO Journal Ophthalmology and stated that the trial had exhibited the long-term efficacy and safety of JETREA as it had resulted to improvement in symptoms indicative of sVMA.
ThromboGenics CEO Dr Patrik De Haes said: "We are pleased that the positive results from this Phase IIIb, randomised controlled trial have now been published in the prestigious AAO Journal Ophthalmology.
“We are confident that the OASIS data will provide very helpful guidance to the global retina community in their assessment of JETREA as an effective and safe treatment option for an important group of patients with symptomatic VMA."
The results of the study, along with its sub study, will be released at upcoming US and global retina specialists educational meetings.